Prevalence of APC and PTEN Alterations in Urachal Cancer.
Adenocarcinoma
/ genetics
Adenomatous Polyposis Coli Protein
/ genetics
Adult
Aged
Biomarkers, Tumor
/ genetics
Cystectomy
/ mortality
Female
Follow-Up Studies
Humans
Male
Middle Aged
Mutation
PTEN Phosphohydrolase
/ genetics
Prevalence
Prognosis
Retrospective Studies
Survival Rate
Urinary Bladder Neoplasms
/ genetics
Wnt Signaling Pathway
Young Adult
beta Catenin
/ genetics
APC
Colorectal cancer
Molecular genetics
Mutation
Urachal cancer
ß-catenin
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
02
03
2020
accepted:
07
07
2020
pubmed:
6
8
2020
medline:
13
7
2021
entrez:
6
8
2020
Statut:
ppublish
Résumé
Urachal carcinoma (UrC) is a rare tumor with remarkable histological and molecular similarities to colorectal cancer (CRC). Adenomatous polyposis coli (APC) is the most frequently affected gene in CRC, but the prevalence and significance of its alterations in UrC is poorly understood. In addition, loss of phosphatase and tensin homologue (PTEN) was shown to be associated with therapy resistance in CRC. Our primary aim was to assess specific genetic alterations including APC and PTEN in a large series of UrC samples in order to identify clinically significant genomic alterations. We analyzed a total of 40 UrC cases. Targeted 5-gene (APC, PTEN, DICER1, PRKAR1A, TSHR, WRN) panel sequencing was performed on the Illumina MiSeq platform (n = 34). In addition, ß-catenin (n = 38) and PTEN (n = 30) expressions were assessed by immunohistochemistry. APC and PTEN genes were affected in 15% (5/34) and 6% (2/34) of cases. Two of five APC alterations (p.Y1075*, p.K1199*) were truncating pathogenic mutations. One of the two PTEN variants was a pathogenic frameshift insertion (p.C211fs). In 29% (11/38) of samples, at least some weak nuclear ß-catenin immunostaining was detected and PTEN loss was observed in 20% (6/30) of samples. The low prevalence of APC mutations in UrC represents a characteristic difference to CRC. Based on APC and ß-catenin results, the Wnt pathway seems to be rarely affected in UrC. Considering the formerly described involvement of PTEN protein loss in anti-EGFR therapy-resistance its immunohistochemical testing may have therapeutic relevance.
Identifiants
pubmed: 32754865
doi: 10.1007/s12253-020-00872-6
pii: 10.1007/s12253-020-00872-6
pmc: PMC7471184
doi:
Substances chimiques
APC protein, human
0
Adenomatous Polyposis Coli Protein
0
Biomarkers, Tumor
0
beta Catenin
0
PTEN Phosphohydrolase
EC 3.1.3.67
PTEN protein, human
EC 3.1.3.67
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2773-2781Subventions
Organisme : Nemzeti Kutatási, Fejlesztési és Innovaciós Alap (HU)
ID : NKFIH / PD 115616
Organisme : Nemzeti Versenyképességi és Kiválósági Program
ID : 16-1-2016-004
Références
Diagn Pathol. 2012 Nov 02;7:151
pubmed: 23121893
J Biomed Sci. 2016 Jan 19;23:9
pubmed: 26787105
Clin Genitourin Cancer. 2016 Aug;14(4):e449-52
pubmed: 27102403
Eur Urol. 2016 Nov;70(5):771-775
pubmed: 27178450
Virchows Arch. 2019 Jan;474(1):13-20
pubmed: 30302546
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Int J Cancer. 2018 Oct 1;143(7):1764-1773
pubmed: 29672836
Urol Oncol. 2016 Sep;34(9):388-98
pubmed: 27267737
Pol J Pathol. 2016 Jun;67(2):156-62
pubmed: 27543871
Hum Pathol. 2014 Feb;45(2):327-30
pubmed: 24355196
Clin Cancer Res. 2004 Feb 15;10(4):1401-8
pubmed: 14977843
J Med Genet. 2017 Aug;54(8):572-578
pubmed: 28348108
J Cancer Res Ther. 2014 Jul-Sep;10(3):571-4
pubmed: 25313741
Pathology. 2017 Apr;49(3):316-317
pubmed: 28285720
Am J Surg Pathol. 2014 Aug;38(8):1033-45
pubmed: 25025366
Oncotarget. 2016 May 17;7(20):29211-5
pubmed: 27078850
J Urol. 1982 Jan;127(1):40-2
pubmed: 7057501
BMC Cancer. 2016 Feb 29;16:170
pubmed: 26925973
Oncotarget. 2016 Jun 28;7(26):39293-39301
pubmed: 27283768
J Urol. 1984 Jan;131(1):1-8
pubmed: 6361280
Ann Oncol. 2009 Jan;20(1):84-90
pubmed: 18669866
Dis Markers. 2018 Mar 12;2018:7308168
pubmed: 29721106
Br J Cancer. 2007 Oct 22;97(8):1139-45
pubmed: 17940504
J Cell Sci. 2007 Oct 1;120(Pt 19):3327-35
pubmed: 17881494